This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Akar, N. Articles by Deda, G. Search for Related Content PubMed PubMed Citation Articles by Akar, N. Articles by Deda, G. Pubmed/NCBI databases Gene GEO Profiles HomoloGene UniGene Substance via MeSH Genetics Home Reference Social Bookmarking                   What's this?

Plasminogen Activator Inhibitor-1 4G/5G Polymorphism in Turkish Children With Cerebral Infarct and Effect on Factor V 1691 A Mutation

Ece Akar, BSc, BA

Erkan Yilmaz, BSc, BA

Department of Pediatric Molecular Genetics

Giilhis Deda, MD

Department of Pediatric Neurology, Ankara University ' Ankara, Turkey

The thrombotic risk of carrying plasminogen activator inhibitor-1-675 4G allele was found to be controversial in previous studies. The aim of this study was to evaluate the possible effect of plasminogen activator inhibitor-1 4G/5G polymorphism in the pathogenesis of childhood stroke. The case-control study included 43 patients with cerebral infarct who were below the age of 18 years (range, 10 months to 18 years) and 113 healthy unrelated individuals without family histories of thrombosis. Plasminogen activator inhibitor-1 4G/5G polymorphism was analyzed according to a previously described method. There was no statistically significant difference in patient and control groups for the distribution of plasminogen activator inhibitor-1 4G/5G polymorphism (P = .75) (allele frequency 4G controls: 0.50; patients: 0.53). However, there was a significant difference for the factor V (FV) 1691 A mutation for both groups (P = .0007). (J Child Neurol 2001;16:294-295).

Journal of Child Neurology, Vol. 16, No. 4, 294-295 (2001)
DOI: 10.1177/088307380101600413


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				D. C. Herak, M. R. Antolic, J. L. Krleza, M. Pavic, S. Dodig, V. Duranovic, A. B. Brkic, and R. Zadro Inherited Prothrombotic Risk Factors in Children With Stroke, Transient Ischemic Attack, or Migraine Pediatrics, April 1, 2009; 123(4): e653 - e660. [Abstract] [Full Text] [PDF]

				D. Ozel Demiralp, H. Aktas, and N. Akar The Effect of Plasminogen Activator Inhibitor-1 -675 4G/5G Polymorphism on PAI-1 Gene Expression and Adipocyte Differentiation Clinical and Applied Thrombosis/Hemostasis, October 1, 2008; 14(4): 438 - 446. [Abstract] [PDF]

				E. Ozyurek, G. Balta, A. Degerliyurt, H. Parlak, S. Aysun, and A. Gurgey Significance of Factor V, Prothrombin, MTHFR, and PAI-1 Genotypes in Childhood Cerebral Thrombosis Clinical and Applied Thrombosis/Hemostasis, April 1, 2007; 13(2): 154 - 160. [Abstract] [PDF]

				E. A. Vagiakou, K. A. Voudris, Y. Dimitriou, A. Skardoutsou, and S. Mastroyianni Different Additional Risk Factors for Cerebral Infarctions Associated With the Factor V Leiden Mutation in a Family J Child Neurol, October 1, 2006; 21(10): 903 - 907. [Abstract] [PDF]

				K. Juul, A. Tybjarg-Hansen, R. Steffensen, S. Kofoed, G. Jensen, and B. G. Nordestgaard Factor V Leiden: The Copenhagen City Heart Study and 2 meta-analyses Blood, June 17, 2002; 100(1): 3 - 10. [Abstract] [Full Text] [PDF]